A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients

被引:116
|
作者
Charpentier, B [1 ]
Rostaing, L
Berthoux, F
Lang, P
Civati, G
Touraine, JL
Squifflet, JP
Vialtel, P
Abramowicz, D
Mourad, G
Wolf, P
Cassuto, E
Moulin, B
Rifle, G
Pruna, A
Merville, P
Mignon, F
Legendre, C
Le Pogamp, P
Lebranchu, Y
Toupance, O
de Ligny, BH
Touchard, G
Olmer, M
Purgus, R
Pouteil-Noble, C
Glotz, D
Bourbigot, B
Leski, M
Wauters, JP
Kessler, M
机构
[1] Hop Bicetre, Serv Nephrol, Le Kremlin Bicetre, France
[2] CHU Toulouse, Hop Rangueil, Unite Transplantat Organes, Toulouse, France
[3] Hop Nord St Etienne, Serv Nephrol & Transplantat, St Etienne, France
[4] Hop Henri Mondor, Serv Nephrol, F-94010 Creteil, France
[5] Azienda Osped Osped Niguarda Ca Granda, Div Nefrol & Dialisi, Milan, Italy
[6] Hop Edouard Herriot, Serv Transplantat & Immunol Clin, Lyon, France
[7] Clin Univ St Luc, Serv Transplantat Renale & Chirurg Glandes Endocr, B-1200 Brussels, Belgium
[8] CHU Nord, Hop Michallon, Serv Nephrol & Transplanatat, Grenoble, France
[9] Clin Univ Hop Erasme, Dept Nephrol, Brussels, Belgium
[10] Hop Lapeyronie, Serv Chirurg Gen & Transplantat, F-34059 Montpellier, France
[11] Hop Hautepierre, Serv Chirurg Gen & Transplantat Multiorganes, Strasbourg, France
[12] Hop Louis Pasteur, Serv Nephrol, Nice, France
[13] Hop Civil, Serv Nephrol & Hemodialyse, Strasbourg, France
[14] Hop Bocage, Serv Nephrol & Reanimat Metab, Dijon, France
[15] CHU Amiens, Hop Sud, Serv Nephrol, Amiens, France
[16] Hop Pellegrin, Serv Nephrol, F-33076 Bordeaux, France
[17] Hop Bichat Claude Bernard, Serv Nephrol, Paris, France
[18] Hop St Louis, Serv Nephrol, Paris, France
[19] CHU Pontchaillou, Serv Nephrol, Rennes, France
[20] Hop Bretonneau, Serv Nephrol, Tours, France
[21] Hop Maison Blanche, Serv Nephrol, Reims, France
[22] Hop Clemenceau, Serv Nephrol & Hemodialyse, Caen, France
[23] Cite Hosp Miletrie, Poitiers, France
[24] Hop Conception, Serv Nephrol & Hemodialyse, Marseille, France
[25] Ctr Hosp Lyon Sud, Serv Nephrol, F-69310 Pierre Benite, France
[26] Hop Georges Pompidou, Serv Nephrol, Paris, France
[27] Hop Cavale Blanche, Serv Nephrol, Brest, France
[28] Univ Geneva, Hop Cantonal, Div Nephrol, Dept Med, CH-1211 Geneva, Switzerland
[29] CHU Vaudois, Div Nephrol, Dept Med, CH-1011 Lausanne, Switzerland
[30] CHU Nancy, Hop Brabois, Serv Nephrol & Transplantat, Vandoeuvre Les Nancy, France
关键词
D O I
10.1097/01.TP.0000056635.59888.EF
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Induction therapy with antithymocyte globulin (ATG) reduces the incidence of acute rejection after transplantation. A study was undertaken to assess the efficacy and safety of ATG induction on tacrolimus-based and cyclosporine A (CsA)-based therapies compared with immediate tacrolimus triple therapy in kidney transplant recipients. Methods. In a 6-month, open-label, randomized, prospective study conducted in 30 European centers, 555 renal transplant patients were randomly assigned to tacrolimus triple therapy (Tac triple, n=185), ATG induction with tacrolimus (ATG-Tac, n= 186), or ATG induction with CsA microemulsion (ATG-CsA, n=184); all were combined with azathioprine, and corticosteroids. The primary endpoint was incidence and time to first acute rejection episode confirmed by biopsy. Results. Patient demographics and clinical parameters at baseline were similar. Patient and graft survival rates were similar in all groups. The incidence of clinically apparent acute rejection was significantly higher (P=0.003) for Tac triple (33.0%) compared with ATG-Tac (22.6%) and the incidence for ATG-Tac was significantly lower (P=0.004) than for ATG-CsA (37.0%). The incidences of acute rejection confirmed by biopsy (primary endpoint) were 25.4%, 15.1%, and 21.2% for Tac triple, ATG-Tac, and ATG-CsA, respectively (Tac triple vs. ATG-Tac, P=0.004). The incidences of corticosteroid-resistant acute rejection were 7.0% (Tac triple), 4.8% (ATG-Tac), and 10.9% (ATG-CsA) (ATG-Tac vs. ATG-CsA, P=0.038). In the ATG groups, the incidences of leukopenia, thrombocytopenia, serum sickness, fever, and cytomegalovirus infection were significantly higher (P<0.05). Conclusions. Acute rejection was significantly lower in the ATG-Tac group compared with the ATG-CsA and Tac triple groups. Significantly more hematologic and infectious adverse events were observed in both ATG induction groups.
引用
收藏
页码:844 / 851
页数:8
相关论文
共 50 条
  • [31] Preoperative single-bolus high-dose antithymocyte globulin as induction therapy in sensitized renal transplant recipients
    Wang Dong
    Wu Wei-zhen
    Yang Shun-liang
    Chen Jin-hua
    Tan Jian-ming
    CHINESE MEDICAL JOURNAL, 2006, 119 (20) : 1683 - 1688
  • [33] Survival with Induction Therapy for Simultaneous Heart-Kidney Transplant Recipients on Tacrolimus/Mycophenolate
    Amin, A. A.
    Ariyamuthu, V. K.
    Urey, M. A.
    Araj, F. G.
    Drazner, M. H.
    Mammen, P. P.
    Tanriover, B.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2017, 36 (04): : S300 - S300
  • [34] Evaluation of clinical outcomes in kidney transplant recipients receiving rabbit antithymocyte globulin induction and tacrolimus within 7 days post-transplant.
    Jackson, John
    Duhart, Benjamin, Jr.
    PHARMACOTHERAPY, 2014, 34 (10): : E292 - E292
  • [35] POPULATION PHARMACOKINETICS OF IMMEDIATE-RELEASE TACROLIMUS IN STEROID-FREE ADULT RENAL TRANSPLANT RECIPIENTS
    Rong, Yan
    Mayo, Patrick
    Ensom, Mary H. H.
    Kiang, Tony K. L.
    DRUG METABOLISM AND PHARMACOKINETICS, 2019, 34 (01) : S66 - S66
  • [36] Prospective Randomized Study of Low Dose Antithymocyte Globulin as Induction in Non Sensitized Adult Renal Transplant Recipients.
    Grafals, M.
    Simpson, M.
    Gilligan, H.
    Pomposelli, J.
    Akoad, M.
    Kwaja, K.
    Trabucco, A.
    Hamill, K.
    Pomfret, E.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 430 - 430
  • [37] Safety and Feasibility of Outpatient Rabbit Antithymocyte Globulin Induction Therapy Administration in Kidney Transplant Recipients
    Varga, Alexandra N.
    Johnson, David
    Sawinski, Deirdre L.
    Lim, Mary Ann
    Bloom, Roy D.
    Abt, Peter L.
    Goral, Simin
    Bleicher, Melissa
    Levine, Matthew H.
    Naji, Ali
    Nazarian, Susanna
    Porrett, Paige
    Trofe-Clark, Jennifer
    PHARMACOTHERAPY, 2018, 38 (06): : 620 - 627
  • [38] Combination therapy of tacrolimus (FK506) with azathioprine and steroids in renal transplant recipients
    Yoshimura, N
    Oka, T
    Ohmori, Y
    Yasumura, T
    Nakai, I
    Hamashima, T
    Nakajima, H
    Okamoto, M
    Nakamura, K
    Mizuta, N
    TRANSPLANTATION PROCEEDINGS, 1998, 30 (01) : 33 - 35
  • [39] Rescue therapy with tacrolimus (FK506) in renal transplant recipients - A multicenter analysis
    Felldin, M
    Backman, L
    Brattstrom, C
    Bentdal, O
    Nordal, K
    Claesson, K
    Persson, NH
    TRANSPLANTATION PROCEEDINGS, 1995, 27 (06) : 3425 - 3425
  • [40] Rescue therapy with tacrolimus (FK 506) in renal transplant recipients - A Scandinavian multicenter analysis
    Felldin, M
    Backman, L
    Brattstrom, C
    Bentdal, O
    Nordal, K
    Claesson, K
    Persson, NH
    TRANSPLANT INTERNATIONAL, 1997, 10 (01) : 13 - 18